Instituto de Enfermedades Crónico Degenerativas, Departamento de Biología Molecular y Genómica, CUCS, Universidad de Guadalajara, Sierra Mojada # 950, Colonia Independencia, CP 44340, Guadalajara, Jalisco, Mexico.
Instituto Transdisciplinar de Investigación y Servicios, CUCEI, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
BMC Immunol. 2020 Mar 6;21(1):9. doi: 10.1186/s12865-020-0341-9.
B7-H6 has been revealed as an endogenous immunoligand expressed in a variety of tumors, but not expressed in healthy tissues. Heretofore, no studies have been reported describing B7-H6 in women with cervical cancer. To investigate this question, our present study was conducted.
This retrospective study comprised a total of 62 paraffinized cervical biopsies, which were distributed in five groups: low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), squamous cervical carcinoma (SCC), uterine cervical adenocarcinoma (UCAC), and a group of cervicitis (as a control for non-abnormal/non-transformed cells). Cervical sections were stained by immunohistochemistry to explore the expression of B7-H6, which was reported according to the immunoreactive score (IRS) system. We observed a complete lack of B7-H6 in LSIL abnormal epithelial cells. Interestingly, B7-H6 began to be seen in HSIL abnormal epithelial cells; more than half of this group had B7-H6 positive cells, with staining characterized by a cytoplasmic and membranous pattern. B7-H6 in the SCC group was also seen in the majority of the sections, showing the same cytoplasmic and membranous pattern. Strong evidence of B7-H6 was notably found in UCAC tumor columnar cells (in 100% of the specimens, also with cytoplasmic and membranous pattern). Moreover, consistent B7-H6 staining was observed in infiltrating plasma cells in all groups.
B7-H6 IRS positively correlated with disease stage in the development of cervical cancer; additionally, B7-H6 scores were found to be even higher in the more aggressive uterine cervical adenocarcinoma, suggesting a possible future therapeutic target for this cancer type.
B7-H6 已被揭示为一种在多种肿瘤中表达的内源性免疫配体,但在健康组织中不表达。迄今为止,尚无研究描述宫颈癌患者中的 B7-H6。为了研究这个问题,我们进行了本研究。
这项回顾性研究共包括 62 例石蜡包埋的宫颈活检组织,分为五组:低级别鳞状上皮内病变(LSIL)、高级别鳞状上皮内病变(HSIL)、鳞状宫颈癌(SCC)、子宫颈腺癌(UCAC)和一组宫颈炎(作为非异常/非转化细胞的对照)。通过免疫组织化学染色探索 B7-H6 的表达,根据免疫反应评分(IRS)系统报告。我们观察到 LSIL 异常上皮细胞中完全缺乏 B7-H6。有趣的是,HSIL 异常上皮细胞中开始出现 B7-H6;超过一半的 HSIL 异常上皮细胞中有 B7-H6 阳性细胞,其染色特征为细胞质和膜性模式。SCC 组中的 B7-H6 也在大多数切片中可见,表现出相同的细胞质和膜性模式。在 UCAC 肿瘤柱状细胞中明显发现了强烈的 B7-H6 证据(在 100%的标本中,也具有细胞质和膜性模式)。此外,在所有组中浸润性浆细胞均观察到一致的 B7-H6 染色。
B7-H6 IRS 与宫颈癌发展过程中的疾病阶段呈正相关;此外,在侵袭性更强的子宫颈腺癌中发现 B7-H6 评分更高,提示该癌症类型可能存在未来的治疗靶点。